1393845-78-7 Usage
Molecular Structure
The compound has a complex structure consisting of a pyrazolo[4,3-b]pyridine ring system and a carboxylic acid group esterified with a tert-butyl group.
Use as Building Block
The compound is used as a building block in the synthesis of pharmaceuticals and biologically active compounds due to its unique structure and potential for forming bioactive molecules.
Potential Applications
The compound has potential applications in the development of new drugs targeting various diseases and disorders.
Tert-Butyl Ester Group
The compound's tert-butyl ester group provides protection to the carboxylic acid group, allowing for controlled release of the compound in the body.
Value in Drug Design and Delivery
The compound is a valuable tool for drug design and delivery due to its ability to control the release of the compound in the body.
Check Digit Verification of cas no
The CAS Registry Mumber 1393845-78-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,3,8,4 and 5 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1393845-78:
(9*1)+(8*3)+(7*9)+(6*3)+(5*8)+(4*4)+(3*5)+(2*7)+(1*8)=207
207 % 10 = 7
So 1393845-78-7 is a valid CAS Registry Number.
1393845-78-7Relevant articles and documents
Preparation method of 4-Boc-2,5,6,7-tetrahydropyrazole[4,3-b]pyridine and derivatives thereof
-
Paragraph 0026-0027, (2020/12/09)
The invention discloses a synthesizing method of 4-Boc-2,5,6,7-tetrahydropyrazole[4,3-b]pyridine and derivatives thereof. The synthesizing method includes condensation reaction and cyclization reaction. The condensation reaction takes formula I (N-Boc-3-p
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00369-00370, (2017/03/21)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
ANTAGONISTS OF CHEMOKINE RECEPTORS
-
Paragraph 0103; 0104, (2014/03/24)
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
